Revenue → Gross profit: $17.0BDiabetes care → Revenue: $15.0BGLP-1 → Diabetes care: $10.8BGross profit → Operating profit: $8.7BGross profit → Operating cost: $8.3BOperating profit → Net profit: $6.8BOperating cost → Sales & distribution: $4.2BInsulin → Diabetes care: $4.0BObesity care → Revenue: $3.7BOperating cost → R&D: $3.7BRevenue → Cost of sales: $3.0BOperating profit → Tax: $1.8BRare disease → Revenue: $1.3BOperating cost → Administrative costs: $0.3BOther diabetes → Diabetes care: $0.2BOperating profit → Financial items: $0.1BOperating cost → Other costs: $0.0BRare disease: $1.3BRevenue: $20.0BObesity care: $3.7BDiabetes care: $15.0BInsulin: $4.0BGLP-1: $10.8BOther diabetes: $0.2BCost of sales: $3.0BGross profit: $17.0BOperating cost: $8.3BSales & distribution: $4.2BR&D: $3.7BAdministrative costs: $0.3BOther costs: $0.0BOperating profit: $8.7BFinancial items: $0.1BTax: $1.8BNet profit: $6.8Bcreated with SankeyArt.comRare disease$1.3B-4% Y/YRevenue$20.0B24% Y/YObesity care$3.7B37% Y/YDiabetes care$15.0B24% Y/YInsulin$4.0B9% Y/YGLP-1$10.8B32% Y/YOther diabetes$0.2B-20% Y/YCost of sales$3.0B390% Y/YGross profit$17.0B24% Y/YOperating cost$8.3B30% Y/YSales & distribution$4.2B5% Y/YR&D$3.7B79% Y/YAdministrative costs$0.3B8% Y/YOther costs$0.0BOperating profit$8.7B18% Y/YFinancial items$0.1BTax$1.8B21% Y/YNet profit$6.8B16% Y/YNovo Nordisk H1 FY24 Income Statement
2023
Full Year
2024
H1